Surgery after chemotherapy is more viable for stage 2 pancreatic cancer patients
Patients with stage 2 pancreatic cancer who receive chemotherapy followed by resection live nearly twice as long as patients who receive only chemotherapy, according to a study drove by the Journal of the American College of Surgeons.
In stage II patients, there is a chance that pancreatic cancer can be removed by resection even after it has spread close to blood vessels. Although chemotherapy can improve outcomes, the risk of surgery is justified because the patients live longer even if the cancerous tissue is not entirely removed, according to a study from researchers at the University of Arizona Department of Surgery, Tucson.
The researchers found that patients who received chemotherapy followed by resection lived an average of 19.75 months, while those who received only chemotherapy lived an average of 10.12 months. They examined data from the National Cancer Database (NCDB), a joint program of the American College of Surgeons and the American Cancer Society.
"Our results show that surgery is viable in more cases than we thought," said Amanda K. Arrington, MD, MHM, FACS, a surgical oncologist at the University of Arizona Department of Surgery, Tucson.
Pancreatic cancer is the fourth leading cause of cancer deaths in men and women in the US 1,2 Survival rates for pancreatic cancer are low because it is a fairly aggressive, fast-growing cancer, Dr. Arrington said. Approximately 10 to 30 percent of these patients present with the disease in which resection may be considered appropriate therapy. Chemotherapy can improve the chances for successful surgery, as about one in three borderline cases are resectable following chemotherapy.3 Even after surgery, however, it is common for pancreatic cancer to return.
While the goal of resection is to remove all of the tumour tissue, it can be difficult to accomplish, especially if cancer has spread to nearby blood vessels that feed the liver and small intestine.
Margin status, or how much cancerous tissue is left post-surgery on the edges of the resected area, is a significant predictor of survival after surgery for pancreatic cancer. Patients with no cancerous tissue left after resection (R0) have improved survival compared with patients with microscopic amounts (R1) or macroscopic amounts (R2) of cancerous tissue left after resection. This study looked at R1 and R2 resection outcomes compared with chemotherapy alone.
Dr. Arrington and her colleagues searched NCDB data from 2010 to 2015 for stage II pancreatic cancer patients who underwent R1/R2 surgery with or without pre-operational chemotherapy to compare to stage II patients who received chemotherapy alone. They found:
1. Out of a total of 11,699 stage II pancreatic cancer patients, 9,521 (81.4 percent) were treated with chemotherapy alone, while 2,178 (18.6 percent) underwent surgical resection and had positive margins (R1 or R2).
2. Of the surgical group, 1,836 (84.3 percent) underwent upfront surgery and 342 (15.7 percent) had chemotherapy followed by surgery.
3. The R1 or R2 patients that had chemotherapy before resection had the best overall survival at a mean of 19.75 months, followed by the upfront surgery group with a mean survival of 17.77 months, and the chemotherapy alone group with a mean survival of 10.12 months.
The data were analyzed in multiple ways to address potential bias; all analyses of the data delivered the same findings.
Study results confirm current recommendations for stage II pancreatic cancer, which note that survival improves when patients receive multimodality therapy, chemotherapy before and/or after resection.
Further, patients benefit from surgery even in extremely difficult cases that end up with a margin positive resection, Dr. Arrington said. The researchers found even when the tumor does not shrink significantly in response to chemotherapy, there are still survival benefits to taking an aggressive surgical approach.
"Based on this study, surgeons can be a little more aggressive and offer surgical treatment more often than not to stage 2 pancreatic cancer patients," Dr. Arrington said. "There are ongoing studies looking at whether more pancreatic cancer patients, including stage I patients, would benefit from surgery after chemotherapy."
Other study authors include Chiu-Hsieh Hsu, PhD; Kenzie L. Schaefer, BS; Catherine L. O'Grady, MPH; Mohammad Khreiss, MD; and Taylor S. Riall, MD, PhD, FACS, all from the University of Arizona.